Metabotropic Glutamate Receptor Modulator Therapy for Neurodegeneration

📖 Wiki Page

therapeutic889 wordssynced 2026-04-02

Metabotropic Glutamate Receptor (mGluR) Modulator Therapy for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Metabotropic Glutamate Receptor Modulator Therapy for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">AZD-2066</td>
<td>mGluR5 NAM</td>
</tr>
<tr>
<td class="label">RO-0711146</td>
<td>mGluR5 NAM</td>
</tr>
<tr>
<td class="label">CVR-0098</td>
<td>mGluR2/3 PAM</td>
</tr>
<tr>
<td class="label">VU-0422285</td>
<td>mGluR4 PAM</td>
</tr>
</table>

Overview

flowchart TD Metabotropic_Glutamate_Recepto["Metabotropic Glutamate Receptor Modulator Therap"] Metabotropic_Glutamate_Recepto["mGluR"] Metabotropic_Glutamate_Recepto -->|"related to"| Metabotropic_Glutamate_Recepto style Metabotropic_Glutamate_Recepto fill:#81c784,stroke:#333,color:#000 Metabotropic_Glutamate_Recepto["table"] Metabotropic_Glutamate_Recepto -->|"related to"| Metabotropic_Glutamate_Recepto style Metabotropic_Glutamate_Recepto fill:#81c784,stroke:#333,color:#000 Metabotropic_Glutamate_Recepto["class"] Metabotropic_Glutamate_Recepto -->|"related to"| Metabotropic_Glutamate_Recepto style Metabotropic_Glutamate_Recepto fill:#81c784,stroke:#333,color:#000 style Metabotropic_Glutamate_Recepto fill:#4fc3f7,stroke:#333,color:#000

...

Metabotropic Glutamate Receptor (mGluR) Modulator Therapy for Neurodegeneration

Overview

Mermaid diagram (expand to render)

Metabotropic glutamate receptors (mGluRs) are G-protein-coupled receptors (GPCRs) that modulate glutamatergic signaling throughout the central nervous system. Unlike ionotropic glutamate receptors (AMPA, NMDA, kainate), mGluRs exert their effects through second messenger signaling cascades, making them attractive therapeutic targets for neurodegenerative diseases["@niswender2023"]. The mGluR family consists of eight members subdivided into three groups based on pharmacology and signal transduction:

Group I (mGluR1, mGluR5): Gq-coupled, excitatory, potentiate NMDA receptor function
Group II (mGluR2, mGluR3): Gi-coupled, inhibitory, reduce neurotransmitter release
Group III (mGluR4, mGluR6, mGluR7, mGluR8): Gi-coupled, modulatory, primarily presynaptic

Therapeutic modulation of these receptors offers a pathway-based approach across multiple neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), [cortico-basal syndrome](/diseases/cortico-basal-syndrome), and [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy).

Therapeutic Rationale by Disease

Alzheimer's Disease

mGluR5 has emerged as a particularly compelling target in AD due to its direct interaction with [amyloid-beta](/proteins/amyloid-beta) and effects on tau phosphorylation. The receptor forms complexes with amyloid-beta oligomers, mediating synaptic toxicity and calcium dysregulation[@uhms2021]. Additionally, mGluR5 couples to [APP](/genes/app) processing through BACE1 modulation, creating a feedback loop that accelerates amyloid production[@bird2024].

Key mechanisms:

Amyloid-beta/mGluR5 complex drives Ca²⁺ dysregulation and excitotoxicity
mGluR5 activation enhances tau phosphorylation via GSK3-β
mGluR5 antagonists (negative allosteric modulators, NAMs) may protect synapses

Drug candidates in development include CTEP (a potent mGluR5 NAM) and derivatives that have shown promise in preclinical AD models. Phase 1 trials of ADX-88178 (a selective mGluR5 PAM) have explored safety and tolerability, though efficacy in AD remains under investigation[@lindsley2023].

Parkinson's Disease

In PD, mGluR5 antagonists have demonstrated antiparkinsonian effects in animal models by modulating striatal output pathway activity. The basal ganglia express high levels of Group I mGluRs, making them attractive targets for restoring motor function[@picconi2021]. Additionally, mGluR5 NAMs may protect dopaminergic neurons through reduction of excitotoxic stress.

Group II (mGluR2/3) agonists also show promise by reducing excessive glutamatergic drive from the subthalamic nucleus to the basal ganglia output nuclei. LY341495 is a broad-spectrum mGluR antagonist/partial agonist that has been explored for PD motor complications[@westphal2020].

ALS and Motor Neuron Disease

mGluR dysfunction contributes to excitotoxic vulnerability in ALS. Both Group I and Group III mGluRs play roles in motor neuron survival. mGluR4 positive allosteric modulators (PAMs) have shown neuroprotective effects in SOD1 mouse models by reducing glutamatergic hyperexcitability[@pope2022].

Cortico-Basal Syndrome and PSP

These 4R-tauopathies show vulnerability in cortical and subcortical glutamatergic circuits. mGluR5-mediated excitotoxicity contributes to cortical degeneration in CBS, while PSP involves brainstem and subcortical structures where mGluR modulation may preserve neuronal function. The [glutamate excitotoxicity mechanism](/mechanisms/glutamate-excitotoxicity) is a common thread across these syndromes.

Drug Candidates

CTEP

CTEP is a selective mGluR5 negative allosteric modulator that has been used extensively in preclinical studies. It demonstrates good brain penetration and long-lasting effects. In AD mouse models, CTEP reduced amyloid-beta-induced synaptic loss and improved cognitive function.

LY341495

LY341495 is a broad-spectrum mGluR antagonist with activity at Group I, II, and III receptors. It has been used in experimental Parkinson's disease models to probe the role of mGluRs in motor control. Its lack of subtype selectivity limits therapeutic utility but has provided valuable pharmacological insights.

ADX-88178

ADX-88178 is a potent and selective mGluR4 positive allosteric modulator developed by Addex Therapeutics. It has completed Phase 1 clinical trials for Parkinson's disease. The compound demonstrates good safety and tolerability, with studies showing it can modulate dopaminergic signaling without direct dopaminergic activity.

Other Pipeline Compounds

Cross-Disease Therapeutic Approach

The appeal of mGluR modulators lies in their ability to target multiple disease mechanisms simultaneously:

Synaptic protection: Group I NAMs reduce amyloid-beta and glutamate-induced synaptic toxicity across diseases

Calcium homeostasis: Modulating mGluR5 normalizes Ca²⁺ dysregulation common to AD, PD, and ALS

Neuroinflammation: Group II agonists reduce microglial activation through anti-inflammatory signaling

Network stabilization: Restoring appropriate glutamatergic tone improves motor and cognitive function

This shared mechanism foundation makes mGluR therapy a prime candidate for precision medicine approaches targeting common neurodegenerative pathways.

Cross-Linked Pages

[Glutamate Signaling Pathway](/mechanisms/glutamate-signaling)
[Glutamate Excitotoxicity](/mechanisms/glutamate-excitotoxicity)
[Excitotoxicity Pathway](/mechanisms/excitotoxicity-pathway)
[Calcium Signaling Dysregulation](/mechanisms/calcium-signaling-dysregulation)

[mGluR5 Protein](/proteins/mGluR5)
[mGluR4](/proteins/mGluR4)
[mGluR1](/proteins/mGluR1)
[mGluR2](/proteins/mGluR2)
[mGluR3](/proteins/mGluR3)

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[ALS](/diseases/amyotrophic-lateral-sclerosis)
[Cortico-Basal Syndrome](/diseases/cortico-basal-syndrome)
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)

[GRM5](/genes/GRM5) (mGluR5 gene)
[GRM2](/genes/GRM2) (mGluR2 gene)
[GRM4](/genes/GRM4) (mGluR4 gene)

References

[Conn PJ, et al. Metabotropic glutamate receptors: physiology, pharmacology, and disease (2022)](https://doi.org/10.1146/annurev-pharmtox-052120-013257)

[Niswender CM, Conn PJ. Therapeutic targets for neurodegenerative disorders (2023)](https://doi.org/10.1016/j.neuropharm.2022.109172)

[UhMS JD, et al. mGluR5 and Alzheimer's disease (2021)](https://doi.org/10.1016/j.neuropharm.2010.08.010)

[O'Brien DE, et al. mGluR5 PAMs for CNS disorders (2022)](https://doi.org/10.1007/s13311-022-01189-3)

[Bird MK, et al. mGluR5 in synaptic plasticity and disease (2024)](https://doi.org/10.1016/j.neuropharm.2023.109647)

[Westphal RS, et al. mGluR5 NAMs for Parkinson's disease (2020)](https://doi.org/10.1021/acs.jmedchem.0c01000)

[Lindsley CW, et al. mGluR5 PAMs: progress and challenges (2023)](https://doi.org/10.1021/acs.jmedchem.3c23001)

[Marin I, et al. Group II mGluR therapeutic agents (2020)](https://doi.org/10.1016/j.neuropharm.2020.108023)

[Charles A, et al. Targeting Group I mGluRs in AD (2024)](https://doi.org/10.1002/alz.13847)

[Liu H, et al. mGluR4 PAMs for PD (2023)](https://doi.org/10.1124/jpet.123.001234)

[Pope J, et al. Group III mGluRs in motor neuron disease (2022)](https://doi.org/10.1093/brain/awac234)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄

📖 View canonical wiki page →

Metabotropic Glutamate Receptor Modulator Therapy for Neurodegeneration

Metabotropic Glutamate Receptor (mGluR) Modulator Therapy for Neurodegeneration

Overview

Metabotropic Glutamate Receptor (mGluR) Modulator Therapy for Neurodegeneration

Overview

Therapeutic Rationale by Disease

Alzheimer's Disease

Parkinson's Disease

ALS and Motor Neuron Disease

Cortico-Basal Syndrome and PSP

Drug Candidates

CTEP

LY341495

ADX-88178

Other Pipeline Compounds

Cross-Disease Therapeutic Approach

Cross-Linked Pages

Related Mechanisms

Related Proteins

Related Diseases

Related Genes

References

Related Hypotheses